The one MOTS-c-derived compound to enter human trials, and what became of it

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
CB4211 was an analogue of MOTS-c, modified for stability, developed by CohBar for non-alcoholic fatty liver disease and obesity. A phase 1a safety study in healthy volunteers began in 2019 and a phase 1b in people with obesity and fatty liver followed; the company reported in 2021 reductions in liver fat and body weight relative to placebo in a small group over a few weeks, with the compound tolerated. The programme was not advanced to later phases and the company subsequently changed direction. It remains the only MOTS-c-related compound to have been given to humans in a controlled study.

What CB4211 was

Not MOTS-c itself but a derivative with chemical modifications intended to extend its half-life and improve its properties as a drug. Its exact structure was proprietary. The rationale drew on the 2015 metabolic findings and the AMPK route.

The distinction matters: results for the analogue are not results for the native peptide.

What was reported

The phase 1a found no safety signal in healthy volunteers. The phase 1b, in a small number of participants with obesity and fatty liver, reported favourable changes in liver fat by imaging and in weight compared with placebo, and in some glucose-related measures, over a short period. The results were released by the company rather than in a peer-reviewed paper.

Small, short, and sponsor-reported, which is the appropriate weight to give them.

Why it matters

It is the extent of the human interventional record for the MOTS-c class. Everything else in humans is observational. The native peptide in this catalogue has not been tested in a controlled human study, and this page states that plainly.

MOTS-c is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
MOTS-c Pack40 mgAED 950In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What CB4211 was?

Not MOTS-c itself but a derivative with chemical modifications intended to extend its half-life and improve its properties as a drug. Its exact structure was proprietary. The rationale drew on the 2015 metabolic findings and the AMPK route.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

MOTS-c Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.